EGFR and non-small cell lung carcinoma: Finally, Lux-Lung 7 was a large randomized phase IIb trial investigating afatinib to gefitinib in 319 treatment-naive patients with stage IIIB or IV NSCLC harboring a del19 or L858R EGFR mutation [96].